| Identification | Back Directory | [Name]
CTA 018 | [CAS]
250384-82-8 | [Synonyms]
CTA 018
MT 2832
Lunacalcipol
(1R,3S,5Z)-5-[(2E)-2-[(3aS,7aS)-1-[(E,2R)-5-tert-butylsulfonylpent-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
1,3-Cyclohexanediol, 5-[(2E)-2-[(3aS,7aS)-1-[(1R,3E)-4-[(1,1-dimethylethyl)sulfonyl]-1-methyl-3-buten-1-yl]-3,3a,5,6,7,7a-hexahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-, (1R,3S,5Z)- | [Molecular Formula]
C28H42O4S | [MDL Number]
MFCD19443721 | [MOL File]
250384-82-8.mol | [Molecular Weight]
474.7 |
| Hazard Information | Back Directory | [Uses]
Lunacalcipol (CTA-018), as a vitamin D analogue, has a dual role in the pathogenesis of Chronic Kidney Disease (CKD), as an agonist of vitamin D receptor and an antagonist of cytochrome P450 enzyme 24-hydroxylase. Lunacalcipol binds to VDR and regulates transcriptional activity of VDR by influencing ligand binding affinity, ligand-dependent coactivator recruitment or inhibitory factor dissociation, efficiency of ligand entry into target cells, tissue specificity and different metabolism of ligand. Lunacalcipol can be used in the study of CKD, especially Secondary Hyperparathyroidism (sHPT)[1]. | [Definition]
ChEBI: Lunacalcipol is a vitamin D. | [References]
[1] Nagamani S, et al. A theoretical insight to understand the molecular mechanism of dual target ligand CTA-018 in the chronic kidney disease pathogenesis[J]. PloS one, 2018, 13(10): e0203194. DOI:10.1371/journal.pone.0203194 |
|
|